Frova Side Effects

Please note - some side effects for Frova may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).

Side Effects of Frova - for the Consumer

Frova

All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome when using Frova:

Dizziness; drowsiness; dry mouth; fatigue; flushing; headache; hot or cold sensations; indigestion; numbness or tingling in the arms, legs, hands, or feet.

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); bloody diarrhea; bone or joint pain; confusion, slurred speech, or changes in vision; hallucinations; irregular or rapid heartbeat; loss of coordination; mental or mood changes (eg, agitation); muscle spasms; one-sided weakness; pain or unusual coldness in feet, legs, hands, or arms; pain, tightness, pressure, and heaviness in the chest, throat, neck, or jaw; pale or blue-colored fingers or toes; persistent numbness or tingling in the arms, legs, hands, or feet; seizures; severe stomach pain; sudden severe dizziness, fainting, headache, or vomiting; sudden shortness of breath.

Frovatriptan

All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome when using Frovatriptan:

Dizziness; drowsiness; dry mouth; fatigue; flushing; headache; hot or cold sensations; indigestion; numbness or tingling in the arms, legs, hands, or feet.

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); bloody diarrhea; bone or joint pain; confusion, slurred speech, or changes in vision; hallucinations; irregular or rapid heartbeat; loss of coordination; mental or mood changes (eg, agitation); muscle spasms; one-sided weakness; pain or unusual coldness in feet, legs, hands, or arms; pain, tightness, pressure, and heaviness in the chest, throat, neck, or jaw; pale or blue-colored fingers or toes; persistent numbness or tingling in the arms, legs, hands, or feet; seizures; severe stomach pain; sudden severe dizziness, fainting, headache, or vomiting; sudden shortness of breath.

Frova Side Effects - for the Professional

Frova

Serious cardiac events, including some that have been fatal, have occurred following use of 5-HT1 agonists. These events are extremely rare and most have been reported in patients with risk factors predictive of CAD. Events reported have included coronary artery vasospasm, transient myocardial ischemia, myocardial infarction, ventricular tachycardia and ventricular fibrillation.

Incidence in Controlled Clinical Trials:

Among 1554 patients treated with Frova in four placebo-controlled trials (Trials 1, 3, 4 and 5 in Table 1), only 1% (16) patients withdrew because of treatment-emergent adverse events. In a long term, open-label study where patients were allowed to treat multiple migraine attacks with Frova for up to 1 year, 5% (26/496) patients discontinued due to treatment-emergent adverse events.

The treatment-emergent adverse events that occurred most frequently following administration of Frovatriptan 2.5 mg (i.e., in at least 2% of patients), and at an incidence ≥1% greater than with placebo, in the four placebo-controlled trials were dizziness, paresthesia, headache, dry mouth, fatigue, flushing, hot or cold sensation and chest pain.

Table 2 lists treatment-emergent adverse events reported within 48 hours of drug administration that occurred with Frovatriptan 2.5 mg at an incidence of ≥ 2% and more often than on placebo, in the first attack in four placebo-controlled trials (Trials 1, 3, 4 and 5 in Table 1). These studies involved 2392 patients (1554 Frovatriptan 2.5 mg and 838 placebo). The events cited reflect experience gained under closely monitored conditions of clinical trials in a highly selected patient population. In actual clinical practice or in other clinical trials, these incidence estimates may not apply, as the conditions of use, reporting behavior, and the kinds of patients treated may differ.

Other events that occurred at ≥2% on Frovatriptan that were equally or more common in the placebo group were somnolence and nausea.

Frova is generally well tolerated. The incidence of adverse events in clinical trials did not increase when up to 3 doses were used within 24 hours. The majority of adverse events were mild or moderate and transient. The incidence of adverse events in four placebo-controlled clinical trials was not affected by gender, age or concomitant medications commonly used by migraine patients. There were insufficient data to assess the impact of race on the incidence of adverse events.

Other Events Observed in Association with Frova:

In the paragraphs that follow, the incidence of less commonly reported adverse events in four placebo-controlled trials are presented. Variability associated with adverse event reporting, the terminology used to describe adverse events etc, limit the value of the incidence estimates provided. The incidence of each adverse event is calculated as the number of patients reporting the event at least once divided by the number of patients who used Frova. All adverse events reported within 48 hours of drug administration in the first attack in four placebo controlled trials involving 2392 patients (1554 Frovatriptan 2.5 mg and 838 placebo) are included, except those already listed in Table 2, those too general to be informative, those not reasonably associated with the use of the drug and those which occurred at the same or a greater incidence in the placebo group. Events are further classified within body system categories and enumerated in order of decreasing frequency using the following definitions: frequent adverse events are those occurring in at least 1/100 patients, infrequent adverse events are those occurring in between 1/100 and 1/1000 patients, and rare adverse events are those occurring in fewer than 1/1000 patients.

Central and peripheral nervous system: Frequent: dysesthesia and hypoesthesia. Infrequent: tremor, hyperesthesia, migraine aggravated, involuntary muscle contractions, vertigo, ataxia, abnormal gait and speech disorder. Rare: hypertonia, hypotonia, abnormal reflexes and tongue paralysis.

Gastrointestinal: Frequent: vomiting, abdominal pain and diarrhea. Infrequent: dysphagia, flatulence, constipation, anorexia, esophagospasm and saliva increased. Rare: change in bowel habits, cheilitis, eructation, gastroesophageal reflux, hiccup, peptic ulcer, salivary gland pain, stomatitis and toothache.

Body as a whole: Frequent: pain. Infrequent: asthenia, rigors, fever, hot flushes and malaise. Rare: feeling of relaxation, leg pain and edema mouth.

Psychiatric: Frequent: insomnia and anxiety. Infrequent: confusion, nervousness, agitation, euphoria, impaired concentration, depression, emotional lability, amnesia, thinking abnormal and depersonalization. Rare: depression aggravated, abnormal dreaming and personality disorder.

Musculoskeletal: Infrequent: myalgia, back pain, arthralgia, arthrosis, leg cramps and muscle weakness.

Respiratory: Frequent: sinusitis and rhinitis. Infrequent: pharyngitis, dyspnea, hyperventilation and laryngitis.

Vision disorders: Frequent: vision abnormal. Infrequent: eye pain, conjunctivitis and abnormal lacrimation.

Skin and appendages: Frequent: sweating increased. Infrequent: pruritis, and bullous eruption.

Hearing and vestibular disorders: Frequent: tinnitus. Infrequent: ear ache, and hyperacusis.

Heart rate and rhythm: Frequent: palpitation. Infrequent: tachycardia. Rare: bradycardia.

Metabolic and nutritional disorders: Infrequent: thirst and dehydration. Rare: hypocalcemia and hypoglycemia.

Special senses, other disorders: Infrequent: taste perversion.

Urinary system disorders: Infrequent: micturition frequency and polyuria. Rare: nocturia, renal pain and abnormal urine.

Cardiovascular disorders, general: Infrequent: abnormal ECG.

Platelet, bleeding and clotting disorders: Infrequent: epistaxis. Rare: purpura.

Autonomic nervous system: Rare: syncope.

Postmarketing Experience

Because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency. Information is often incomplete so that a definite causal relationship to drug exposure can often not be established.

Central and peripheral nervous system: Seizure.

Side Effects by Body System

Cardiovascular

Cardiovascular side effects, some fatal, have occurred following the use of 5-HT1 agonists. These events are extremely rare and most have been reported in patients with risk factors predictive of CAD. Such effects include coronary artery vasospasm, transient myocardial ischemia, myocardial infarction, ventricular tachycardia, and ventricular fibrillation.

Cardiovascular side effects reported with the use of frovatriptan have included palpitation (>1% of patients) and less frequently, tachycardia, abnormal electrocardiogram (ECG), and bradycardia.

Nervous system

Nervous system side effects reported during clinical trials included dizziness (8% vs. 5% placebo), headache (4% vs. 3% placebo), and paresthesia (4% vs. 2% placebo). Additional nervous system side effects reported with the use of frovatriptan have included infrequent cases of tremor, hyperesthesia, worsened migraine, involuntary muscle contractions, vertigo, ataxia, somnolence, abnormal gait and speech disorder. Hypertonia, hypotonia, syncope, abnormal reflexes and tongue paralysis were rarely reported during clinical trials involving frovatriptan. There have also been postmarketing reports of seizure in close temporal association with triptan use.

General

General side effects reported as frequent with the use of frovatriptan have included pain, fatigue, hot or cold sensation, and chest pain. Other general side effects reported less frequently have included asthenia, rigors, fever, hot flushes and malaise. Rarely reported general side effects of frovatriptan use have included feelings of relaxation, leg pain and mouth edema.

Gastrointestinal

Gastrointestinal side effects reported most often during clinical trials included dry mouth (3% vs. 1% placebo) and dyspepsia (2% vs. 1% placebo). Additional gastrointestinal side effects reported as frequent during clinical trials of frovatriptan have included vomiting, nausea, abdominal pain, and diarrhea. Infrequently reported gastrointestinal side effects have included dysphagia, flatulence, constipation, anorexia, esophagospasm, and increased salivation. Rarely reported gastrointestinal side effects have included a change in bowel habits, chelitis, eructation, gastroesophageal reflux, hiccough, peptic ulcer, salivary gland pain, stomatitis, and toothache.

Psychiatric

Psychiatric side effects reported as having occurred frequently during clinical trials involving frovatriptan have included insomnia and anxiety. Reported as infrequent psychiatric side effects were confusion, nervousness, agitation, euphoria, impaired concentration, depression, emotional lability, amnesia, thinking abnormally, and depersonalization. Reports of aggravated depression, abnormal dreaming, and personality disorder have rarely occurred.

Musculoskeletal

Musculoskeletal side effects reported as having occurred frequently during clinical trials have included skeletal pain (3% vs. 2% placebo). Additional musculoskeletal side effects having occurred infrequently with the use of frovatriptan have included myalgia, back pain, arthralgia, arthrosis, leg cramps, and muscle weakness.

Respiratory

Respiratory side effects reported as having occurred frequently during clinical trials of frovatriptan have included sinusitis and rhinitis. Additional respiratory side effects have included infrequent reports of pharyngitis, dyspnea, hyperventilation and laryngitis.

Ocular

Ocular side effects reported as having occurred frequently during clinical trials involving frovatriptan have included abnormal vision. Infrequently reported ocular side effects have included eye pain, conjunctivitis, and abnormal lacrimation.

Dermatologic

Dermatologic side effects reported as having occurred frequently during clinical trials involving frovatriptan have included increased sweating. Infrequently reported dermatologic side effects have included pruritus and bullous eruption.

Other

Other side effects reported as having occurred frequently during clinical trials involving frovatriptan have included tinnitus. Infrequently reported other side effects have included earache, hyperacusis, and taste perversion.

Genitourinary

Genitourinary side effects have been reported infrequently with the use of frovatriptan and have included increased micturition frequency and polyuria. Additionally, rare reports of nocturia, renal pain, and abnormal urine have occurred.

Metabolic

Metabolic side effects have been reported infrequently with the use of frovatriptan and have included increased thirst and dehydration. Additionally, rare reports of hypocalcemia and hypoglycemia have occurred.

Hematologic

Hematologic side effects have been reported infrequently with the use of frovatriptan and have included epistaxis. Additionally, rare reports of purpura have occurred.

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.